Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The two major classes of antidiabetic drugs, sulfonylureas and metformin, may differentially affect macrovascular complications and mortality in diabetic patients. We compared the long-term effects of glipizide and metformin on the major cardiovascular events in type 2 diabetic patients who had a history of coronary artery disease (CAD). RESEARCH DESIGN AND METHODS: This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. A total of 304 type 2 diabetic patients with CAD, mean age = 63.3 years (range, 36–80 years), were enrolled. Participants were randomly assigned to receive either glipizide (30 mg daily) or metformin (1.5 g daily) for 3 years. The primary end points were times to the composite of recurrent cardiovascular events, including death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke, or arterial revascularization. RESULTS: At the end of study drug administration, both groups achieved a significant decrease in the level of glycated hemoglobin (7.1% in the glipizide group and 7.0% in the metformin group). At a median follow-up of 5.0 years, 91 participants had developed 103 primary end points. Intention-to-treat analysis showed an adjusted hazard ratio (HR) of 0.54 (95% CI 0.30–0.90; P = 0.026) for the composites of cardiovascular events among the patients that received metformin, compared with glipizide. The secondary end points and adverse events were not significantly different between the two groups. CONCLUSIONS: Treatment with metformin for 3 years substantially reduced major cardiovascular events in a median follow-up of 5.0 years compared with glipizide. Our results indicated a potential benefit of metformin therapy on cardiovascular outcomes in high-risk patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Follow-up studies involving metformin appeared to support a potential cardiovascular benefit, but these studies were small and the findings were not robust.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [207]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Cited by
Items 101–200 of 366
Metformin and cardiorenal outcomes in diabetes: A reappraisal
Petrie, J. R., Rossing, P. R., & Campbell, I. W. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13984 · Cited by 49
“the effects of metformin and the SU, glipizide, on CV outcomes in 304 individuals with type 2 diabetes and pre-existing coronary artery disease (documented prior MI or stenosis of ≥50% in a major coronary artery).(13) Average diabetes duration was ~ 6 years, and 9% were receiving insulin.”
Li, T., Providencia, R. A., Jiang, W., Mu, N., Wang, Y., Li, X., Yin, Y., Liu, M., Yu, L., Gu, C., et al. (2022) · Drugs · doi:10.1007/s40265-021-01665-0 · Cited by 50
“Pooled analysis of 5 studies (n = 2923) [29, 34, 37, 39, 42] shows that metformin is associated with a reduction in the incidence of coronary revascularisation (HR: 0.”
BackgroundInfluentialIncreased thrombin generation in women with polycystic ovary syndrome
Glintborg, D., Sidelmann, J. J., Altinok, M. L., Mumm, H., & Andersen, M. (2015) · Metabolism · doi:10.1016/j.metabol.2015.06.011 · Cited by 48
“[10] Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, et al.”
BackgroundShang, F., Zhang, J., Li, Z., Zhang, J., Yin, Y., Wang, Y., Marin, T. L., Gongol, B., Xiao, H., Zhang, Y.-Y., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151845 · Cited by 44
Self-citationMolusky, M. M., Hsieh, J., Lee, S. X., Ramakrishnan, R., Tascau, L., Haeusler, R. A., Accili, D., & Tall, A. R. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311212 · Cited by 46
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 48
Zhou, Y., Suo, W., Zhang, X., Liang, J., Zhao, W., Wang, Y., Li, H., & Ni, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115669 · Cited by 44
Self-citationLuo, F., Guo, Y., Ruan, G., Long, J., Zheng, X., Qin, X., Zhao, S., Peng, D., Fang, Z., & Li, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-02080-w · Cited by 41
Lee, Y., Joo, J., Lee, Y. J., Lee, E. K., Park, S., Kim, T.-S., Lee, S.-H., Kim, S. Y., Wie, G.-A., Park, M., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.011 · Cited by 45
Yan, Y., Li, T., Li, Z., He, M., Wang, D., Xu, Y., Yang, X., Bai, Y., Lao, Y., Zhang, Z., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.690627 · Cited by 50
“It was found that metformin, a hypoglycemic agent, exhibits abilities to suppress the progression of common carotid intima-media thickness in T2DM patients and also reduces the incidence of myocardial infarction (11, 12, 14, 15).”
BackgroundSelf-citationThymoquinone Lowers Blood Glucose and Reduces Oxidative Stress in a Rat Model of Diabetes
Lutfi, M. F., Abdel-Moneim, A.-M. H., Alsharidah, A. S., Mobark, M. A., Abdellatif, A. A. H., Saleem, I. Y., Rugaie, O. A., Mohany, K. M., & Alsharidah, M. S. (2021) · Molecules · doi:10.3390/molecules26082348 · Cited by 43
“When exploring the efficacy of anti-diabetic drugs, having antioxidant effects [8,9], efficacy in correcting dyslipidaemia [10] and hyperglycaemia [11], as well as safety, are crucial.”
BackgroundRani, R., Hajam, Y. A., Kumar, R., Bhat, R. A., Rai, S., & Rather, M. A. (2021) · Phytomedicine Plus · doi:10.1016/j.phyplu.2021.100161 · Cited by 50
Inzucchi, S. E. (2017) · Diabetes Care · doi:10.2337/dc16-2372 · Cited by 50
“SPREAD-DIMCAD (7) (2013) Metformin vs.”
BackgroundInfluentialCardioprotective anti-hyperglycaemic medications: a review of clinical trials
Ahmed, H. M., Khraishah, H., & Cho, L. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx668 · Cited by 45
Targeting ageing and preventing organ degeneration with metformin
Sunjaya, A. P., & Sunjaya, A. F. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.09.009 · Cited by 37
Type 2 Diabetes Medication Review
Sterrett, J., Bragg, S. W., & Weart, C. W. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.01.019 · Cited by 42
“The SPREAD-DIMCAD trial comparing 5 years of treatment with glipizide versus metformin in patients with type 2 diabetes and coronary artery disease also showed a reduction in composite CV events with a 10.1% ARR.22 The NNT to prevent 1 CV death, nonfatal MI, nonfatal stroke, arterial revascularization or all-cause dea…”
BackgroundInfluentialGu, J., Yin, Z., Zhang, J., & Wang, C. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.11.087 · Cited by 38
Dong, X., Hui, T., Chen, J., Zheng, Y., Ren, D., Zou, S., Wang, S., Fei, E., Jiao, H., & Lai, X. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.642908 · Cited by 36
Ma, X., Jiang, Z.-S., Zuo, W., & Zhang, Z. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29112 · Cited by 35
“Furthermore, Met can alleviate cardiovascular complications in patients with T2DM by lowering the level of blood glucose (Hong et al., 2013).”
BackgroundMetformin protects lens epithelial cells against senescence in a naturally aged mouse model
Chen, M., Fu, Y., Wang, X., Wu, R., Su, D., Zhou, N., & Qi, Y. (2022) · Cell Death Discovery · doi:10.1038/s41420-021-00800-w · Cited by 46
The Application of Genomics in Diabetes: Barriers to Discovery and Implementation
Floyd, J. S., & Psaty, B. M. (2016) · Diabetes Care · doi:10.2337/dc16-0738 · Cited by 39
“treatment guidelines for type 2 diabetes (52) permit the use of most approved drug classes as second-line therapy after metformin, which is the recommended first-line therapy for most patients because of its good safety profile and potential cardiovascular benefits (53,54).”
BackgroundYousuf, Y., Datu, A., Barnes, B., Amini‐Nik, S., & Jeschke, M. G. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1480-x · Cited by 36
Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin
Chan, J. C. N., Yang, A., Chu, N. H. S., & Chow, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15700 · Cited by 38
“30 Besides, the weight of observational and real-world evidence points to putative CV-renal benefits of metformin, which will be discussed in the next section.”
Kanie, T., Mizuno, A., Yoneoka, D., Tam, W., Morze, J., Rynkiewicz, A., Xin, Y., Wu, O., & Kwong, J. S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650 · Cited by 34
Harrington, J. L., de Albuquerque Rocha, N., Patel, K. V., Verma, S., & McGuire, D. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1035-z · Cited by 32
Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review
Zhang, Y., Zhou, F., Guan, J., Zhou, L., & Chen, B. (2023) · Biomolecules · doi:10.3390/biom13020250 · Cited by 41
Self-citationChiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 31
Wang, H., Cordiner, R. L. M., Huang, Y., Donnelly, L. A., Hapca, S. M., Collier, A., McKnight, J. A., Kennon, B., Gibb, F. W., McKeigue, P., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1238 · Cited by 35
Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes
Quartuccio, M., Buta, B. J., & Kalyani, R. R. (2017) · Current Geriatrics Reports · doi:10.1007/s13670-017-0215-z · Cited by 32
Boussageon, R., Gueyffier, F., & Cornu, C. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.12.010 · Cited by 30
Singh, A., Donnino, R. M., WEINTRAUB, H. S., & Schwartzbard, A. Z. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.05.044 · Cited by 34
Ismail‐Beigi, F., Moghissi, E. S., Kosiborod, M., & Inzucchi, S. E. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4061-7 · Cited by 28
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
Shah, B. R., BAJAJ, H. S., Butalia, S., Dasgupta, K., Eurich, D. T., Jain, R., Leung, K., Mansell, K. D., & Simpson, S. H. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.08.002 · Cited by 41
Jong, C.-B., Chen, K., Hsieh, M., Su, F., Wu, C., Voon, W., Hsieh, C., Shyu, K., Chong, J., Lin, W., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.03.021 · Cited by 27
Markowicz-Piasecka, M., Huttunen, K. M., Broncel, M., & Sikora, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-43083-z · Cited by 28
Mannucci, E., Monami, M., Candido, R., Pintaudi, B., & Targher, G. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.05.032 · Cited by 29
Ding, Q., Tian, J., Li, M., Lian, F., Zhao, L., Wei, X., Han, L., Zheng, Y., Gao, Z., Yang, H., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.530160 · Cited by 30
“Similar results have also been observed in subsequent clinical studies (Kooy et al., 2009; Hong et al., 2013; Han et al., 2019), which suggested the pleiotropic effects of metformin in the heart and blood vessels, independent of its glucose-lowering activity.”
ResultClinical perspectives and concerns of metformin as an anti‐aging drug
Wang, C., Chen, B., Feng, Q., Nie, C., & Li, T. (2020) · Aging Medicine · doi:10.1002/agm2.12135 · Cited by 30
Volke, V., Katus, U., Johannson, A., Toompere, K., Heinla, K., Rünkorg, K., & Uusküla, A. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01158-5 · Cited by 34
“Importantly, there is a trial with high-risk patients where use of SUs was associated with a significantly increased composite of cardiovascular endpoints [7].”
BackgroundZhang, Y., Hu, C., Hong, J., Zeng, J., Lai, S., Lv, A., Su, Q., Dong, Y., Zhou, Z., Tang, W., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0090 · Cited by 30
Self-citationVascular Complications of Diabetes Mellitus
Chiong, Y., & Evans‐Molina, C. (2014) · Springer eBooks · doi:10.1007/978-3-642-37078-6_49 · Cited by 31
Wu, Z., Jin, T., & Weng, J. (2018) · Science China Life Sciences · doi:10.1007/s11427-018-9377-y · Cited by 29
Dihoum, A., Rena, G., Pearson, E. R., Lang, C. C., & Mordi, I. R. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2196010 · Cited by 33
“Indeed, other randomized trial data have not found any improvements in cholesterol profile (in particular lower LDLcholesterol) with metformin [43,80,81].”
BackgroundBasnet, S., Kozikowski, A., Makaryus, A. N., Pekmezaris, R., Zeltser, R., Akerman, M. B., LESSER, M. L., & Wolf‐Klein, G. P. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002314 · Cited by 28
“cardiovascular events compared with glipizide at 5 years (7 versus 14 deaths, respectively).(25) The GLP-1 receptor agonist exenatide has been demonstrated to be cardioprotective in both animal studies(26) and clinical trials.”
BackgroundFollow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes
Hayward, R. A., Reaven, P. D., & Emanuele, N. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1508386 · Cited by 50
A calibration approach to transportability and data‐fusion with observational data
Josey, K., Yang, F., Ghosh, D., & Raghavan, S. (2022) · Statistics in Medicine · doi:10.1002/sim.9523 · Cited by 44
Kadam, U. T., Roberts, I., White, S. J., Bednall, R., Khunti, K., Nilsson, P. M., & Lawson, C. A. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2018.10.014 · Cited by 33
Luo, F., Guo, Y., Ruan, G., & Li, X. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0281-9 · Cited by 26
“[4] in a multicenter, randomized, double-blind, placebo-controlled clinical trial found”
BackgroundManrique, C. M., & Sowers, J. R. (2014) · Cardiorenal Medicine · doi:10.1159/000368423 · Cited by 24
Cardiovascular effects of anti-diabetes drugs
Younk, L. M., Lamos, E. M., & Davis, S. N. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1195368 · Cited by 24
“As we currently have a focus on vascular protection, we cannot abandon adequate glycemic control, which serves to prevent microvascular complications and reduce CVD in patients with shorter T2DM duration.”
BackgroundInfluentialRahelić, D., Javor, E., Lucijanić, T., & Skelin, M. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1226514 · Cited by 26
“had no significant effect on all-cause mortality (43).”
BackgroundMachini, W. B. S., Fernandes, I. P. G., & Oliveira‐Brett, A. M. (2019) · Electroanalysis · doi:10.1002/elan.201900162 · Cited by 23
Emerging uncertainty on the anti-aging potential of metformin
Keys, M. T., Hallas, J., Miller, R. A., Suissa, S., & Christensen, K. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102817 · Cited by 29
“The SPREAD-DIMCAD trial showed that metformin was associated with a lower risk of major cardiovascular events in direct comparison to the sulfonylurea glipizide (Hong et al., 2013).”
Analysis of potential hub genes involved in the pathogenesis of Chinese type 1 diabetic patients
Yang, S., Cao, C., Xie, Z., & Zhou, Z. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.171 · Cited by 23
“Discussion Diabetes has become one of the most important chronic disease with a rapidly increasing prevalence during the past decade (19).”
BackgroundSelf-citationLong-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes
Donner, T. W., & Joseph, J. J. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s50286 · Cited by 22
Mortality risk with sulphonylureas compared to metformin
Holden, S. E., & Currie, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12280 · Cited by 23
Ji, Q. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.013 · Cited by 24
Gebrie, D., Demsie, D. G., & Manyazewal, T. (2021) · Scientific Reports · doi:10.1038/s41598-020-80603-8 · Cited by 22
Risk of acute atherosclerotic cardiovascular disease in patients with acute and chronic pancreatitis
Sung, L., Chang, C., Lin, C., Yeh, C., Cherng, Y., Chen, T.-L., & Liao, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-99915-4 · Cited by 22
Ong, A. N., Tan, C. C., Cañete, M. T. A., Lim, B. A., & Robles, J. (2021) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.036.02.20 · Cited by 22
Kaku, K., Wanner, C., Anker, S. D., Pocock, S., Yasui, A., Mattheus, M., & Lund, S. S. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14626 · Cited by 20
González‐González, J. G., Solís, R. C., González-Colmenero, A. D., Raygoza-Cortez, K., Moreno-Peña, P. J., Sánchez, A. L., McCoy, R. G., Ospina, N. S., Maraka, S., Brito, J. P., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109821 · Cited by 22
Alsharidah, M. S., Algeffari, M., Abdel-Moneim, A.-M. H., Lutfi, M. F., & Alshelowi, H. (2017) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2017.11.007 · Cited by 20
“However, there is a lack of sufficient reports on the therapeutic benefits of combined metformin/gliclazide therapy on oxidative stress, lipid pro-file, and hepatorenal functions (Hong et al., 2013).”
Plowman, T. J., Christensen, H., Aiges, M., Fernandez, E., Shah, M. H., & Ramana, K. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105190 · Cited by 23
“A multicentered, randomized, double-blind, placebo-controlled study indicated that three years of metformin treatment significantly reduced cardiovascular complications in diabetic patients when compared to glipizide [56].”
BackgroundResultInfluentialThe Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes
Wu, L., & Gunton, J. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235853 · Cited by 20
“studied 304 patients with T2D randomised to receive either glipizide or metformin [14].”
BackgroundEndoplasmic reticulum stress-induced cell death mechanism
Madkour, L. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-822481-6.00012-8 · Cited by 18
Low metformin dose and its therapeutic serum concentration in prediabetes
Sutkowska, E., Fortuna, P., Wiśniewski, J. Ł., Sutkowska, K., Hodurek, P., Gamian, A., & Kałuża, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-91174-7 · Cited by 20
Chen, Y., Du, L., Geng, X., Peng, Y., Shen, J., Zhang, Y., Liu, G., & Sun, X. (2015) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12157 · Cited by 23
“Hasegawa 2008 (38) unclear unclear unclear unclear low risk Hong 2013 (39) unclear conducted by a biostatistician double-blind unclear high risk”
BackgroundSelf-citationBirajdar, S. V., Mazahir, F., & Yadav, A. K. (2023) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2023.2282990 · Cited by 17
Koren-Gluzer, M., Aviram, M., & Hayek, T. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.08.062 · Cited by 17
Lee, Y., Chang, C., Dong, Y., Lin, J., Wu, L., Hwang, J., & Chuang, L. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.022 · Cited by 17
Self-citationBurggraaf, B., & Cabezas, M. C. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.04.017 · Cited by 18
Komaru, Y., Takeuchi, T., Suzuki, L., Asano, T., & Urayama, K. Y. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107511 · Cited by 18
Management standards for stable coronary artery disease in India
Mishra, S., Ray, S., Dalal, J. J., Sawhney, J. P. S., Ramakrishnan, S., Nair, T., Iyengar, S. S., & Bahl, V. K. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2016.11.320 · Cited by 18
Rivas, E., Herndon, D. N., Porter, C. C., Meyer, W. J., & Suman-Vejas, O. E. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00194.2017 · Cited by 19
Protection of diabetes in aortic abdominal aneurysm: Are antidiabetics the real effectors?
Picatoste, B., Cerro-Pardo, I., Blanco‐Colio, L. M., & Martín-Ventura, J. L. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1112430 · Cited by 18
Is metformin a geroprotector? A peek into the current clinical and experimental data
Zajda, A., Huttunen, K. M., Sikora, J., Podsiedlik, M., & Markowicz-Piasecka, M. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111350 · Cited by 16
Dubayee, M. A., Alshahrani, A. S., Almalki, M. H., Hakami, A., Homoud, B., Alzneidi, N., Aldhalaan, J., Aljbli, G., Nasr, A., Farahat, A. I., et al. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107758 · Cited by 16
Management of Hyperglycemia in Older Adults with Type 2 Diabetes
Gandhi, G. Y., & Mooradian, A. D. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00910-1 · Cited by 18
Mannucci, E., & Silverii, G. A. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15226 · Cited by 16
“26 The SPREAD-DIMCAD 27 Overall, available evidence is insufficient to show a significant reduction in the incidence of MACE in patients without ASCVD with any class of drugs for diabetes.”
MethodCardiovascular disease leads to a new algorithm for diabetes treatment
Rodriguez, V., Weiss, M. C., WEINTRAUB, H. S., Goldberg, I. J., & Schwartzbard, A. Z. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.07.004 · Cited by 16
Baik, S. H., & McDonald, C. J. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000940 · Cited by 16
Sohn, M., Frías, J. P., & Lim, S. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15251 · Cited by 17
Ahmed, R., de Souza, R. J., Li, V., Banfield, L. E., & Anand, S. S. (2024) · Diabetologia · doi:10.1007/s00125-023-06052-w · Cited by 16
A blast from the past: To tame time with metformin
Xenos, D., Mecocci, P., & Boccardi, V. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111743 · Cited by 16
GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis
Grenet, G., Ribault, S., Nguyen, G. B., Glais, F., Metge, A., Linet, T., Kassaï, B., Cornu, C., Bejan‐Angoulvant, T., Erpeldinger, S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217701 · Cited by 18
Abualsuod, A. M., Rutland, J. J., Watts, T. E., Pandat, S. S., Delongchamp, R. R., & Mehta, J. L. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6601-x · Cited by 15
Kamel, A. M., Ismail, B., Hafiz, G. A., Sabry, N. A., & Farid, S. F. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0164 · Cited by 15
“44 Conversely, in the REMOVAL trial, carotid intima thickness reduction was associated with HbA1c.”
Cardiovascular events in individuals treated with sulfonylureas or dipeptidyl peptidase 4 inhibitors
Turchin, A., Petito, L. C., Hegermiller, E., Carnahan, R., DeVries, A., Goel, S., Lansang, M. C., McDonnell, M. E., Nair, V., Priest, E., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.23067 · Cited by 14
Diabetes: the place of new therapies
Dhatariya, K. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818807599 · Cited by 14
Discovering Biological Mechanisms of Exceptional Human Health Span and Life SpanPreprint
Milman, S., & Barzilai, N. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041204 · Cited by 14
Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes
Andraos, J., Smith, S. R., Tran, A., & Pham, D. Q. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01406-6 · Cited by 20
“The primary outcome of a composite endpoint of CV death, all-cause death, non-fatal MI, non-fatal stroke, or arterial revascularization was reduced in the metformin group rela - tive to glipizide (HR 0.54; 0.30–0.90) [24 ].”
BackgroundInfluentialDiabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes
Chi, C., SNAITH, J. R., & Gunton, J. E. (2017) · Heart Lung and Circulation · doi:10.1016/j.hlc.2017.02.030 · Cited by 18
“With the high-risk subjects and five-year follow-up, the absolute risk of CV endpoints was 35% in the glipizide group and 25% in the metformin group (13).”
BackgroundCordiner, R. L. M., & Pearson, E. R. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13596 · Cited by 14
Skov, V., Cangemi, C., Gram, J., Christensen, M. M. H., Grodum, E., Sørensen, D., Argraves, W. S., Henriksen, J. E., & Rasmussen, L. M. (2013) · Diabetes Care · doi:10.2337/dc13-1022 · Cited by 14
“(31), metformin therapy was associated to lower mortality and cardiovascular risk when compared to the most common insulin secretagogues, in line with new findings by Hong et al (10).”
ResultInfluentialShah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 23
Yandrapalli, S., Jolly, G. P., Horblitt, A. M., Pemmasani, G., Sanaani, A., Aronow, W. S., & Frishman, W. H. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000308 · Cited by 14
“The mortality benefit of metformin was also seen in patients with previously diagnosed cardiac disease.(57,59) The Reduction of Atherothrombosis for Continued Health (REACH) registry showed an improved mortality with metformin in diabetic patients with established atherothrombosis, an effect that was independent of me…”
BackgroundBanik, S., Hossain, M. S., Bhatta, R., & Akter, M. (2018) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_202_17 · Cited by 12
“Our data are in line with data obtained by other researches,[27] who described that metformin has a potential benefit over glipizide on managing CV outcomes in the high‐risk patient.”
ResultAlemi, H., Khaloo, P., Mansournia, M. A., Rabizadeh, S., Salehi, S. S., Mirmiranpour, H., Meftah, N., Esteghamati, A., & Nakhjavani, M. (2018) · Medicine · doi:10.1097/md.0000000000009791 · Cited by 13
Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights
Sarkar, A., Fanous, K., Marei, I., Ding, H., Ladjimi, M. M., MacDonald, R. S., Hollenberg, M. D., Anderson, T. J., Hill, M. A., & Triggle, C. R. (2024) · Vascular Health and Risk Management · doi:10.2147/vhrm.s391808 · Cited by 11
“194 These data are consistent with the benefits being associated with the anti-diabetes glucose-lowering actions of the agents rather than specifically to the class of drug.”
Background
Metadata
- Authors
- Hong, J., Zhang, Y., Lai, S., Lv, A., Su, Q., Dong, Y., Zhou, Z., Tang, W., Zhao, J., Cui, L., Zou, D., Wang, D., Li, H., Liu, C., Wu, G., Shen, J., Zhu, D., Wang, W., Shen, W., Ning, G., & on behalf of the SPREAD-DIMCAD Investigators
- Affiliations
- Shanghai Jiao Tong University (CN)
- Johns Hopkins University (US)
- Second Xiangya Hospital of Central South University (CN)
- Shandong University (CN)
- Second Military Medical University (CN)
- The First Affiliated Hospital of Wenzhou Medical College, Zhejiang Province, China
- Sir Run Run Shaw Hospital (CN)
- Jiangsu Province Hospital (CN)
- Shanghai Ten’s People’s Hospital of Tongji University, Shanghai, China
- Nanfang Hospital (CN)
- Nanjing Drum Tower Hospital (CN)
- Corresponding author
- Ning, Guang
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-04-13
- Volume
- 36
- Issue
- 5
- Pages
- 1304-1311
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3631843
- OpenAlex
- W2141199290
- Cited by
- 366
- References
- 37
- Citations by year
- 2026: 7 · 2025: 16 · 2024: 20 · 2023: 26 · 2022: 43 · 2021: 35 · 2020: 44 · 2019: 31 · 2018: 31 · 2017: 28 · 2016: 30 · 2015: 20 · 2014: 22 · 2013: 12
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81170784, 1994DP131044, 201002002, 2012ZX09303006-001, 30971077)
- Shanghai Municipal Education Commission
- National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology (2012ZX09303006‐001)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- metformin, glipizide, type 2 diabetes, coronary artery disease, cardiovascular outcomes, sulfonylureas, myocardial infarction, stroke, cardiovascular mortality, HbA1c, macrovascular complications
- MeSH terms
- Adult, Aged, Aged, 80 and over, Coronary Artery Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glipizide, Humans, Male, Metformin, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.